🧠 This Week in Immunology: RA Market Growth, AI in Care, Breakthroughs in AD, Global Regulatory Moves and More
Stay up to date with the latest developments in immunology—from market expansions and AI-powered care to next-gen therapies and regulatory green lights across the globe:
🌏 RA Market Set to Soar in Asia-Pacific, projected to grow from $799.9 million in 2025 to $1.16 billion by 2032—driven by anti-CCP testing, tele-rheumatology, and growing access to biosimilars.
🧠 NHS Prioritizes AI in Chronic Disease Management, with plans to roll out standardized teledermatology hubs by 2028–29, aiming to reduce the UK’s 7.4 million elective waiting list through virtual-first care models.
🌿 Zabalafin Hydrogel Emerges as New Hope for Atopic Dermatitis, showing relief for itch and inflammation, including MRSA targeting, with strong Phase 2a quality-of-life improvements and minimal side effects. Global Phase 2b results expected in early 2026.
💉 Biologic APG777 Achieves 66.9 Percent EASI-75 Response in moderate-to-severe atopic dermatitis, offering dose-dependent efficacy and injection-sparing convenience. Phase 3 and long-term data are due in 2026.
✅ VTAMA Cream Earns Strong AAD Endorsement for Adult AD, based on robust 8- and 48-week trial data. FDA-approved for atopic dermatitis and psoriasis in both adults and children, and praised for being steroid-free with no label restrictions.
🇮🇳 Abrocitinib Receives CDSCO Approval in India for moderate-to-severe atopic dermatitis requiring systemic therapy—backed by Phase III data and approved without conditions or objections.
🇪🇺 EMA Opens New Pathway for Allergy Therapies, offering adaptive guidance for rare allergens in small populations. This new regulatory framework will go into effect in January 2026.
🇰🇷 Genetic Breakthrough in Lupus from South Korea, as researchers reveal a tool to decode the MHC gene cluster, including East Asian-specific variants—paving the way for more personalized treatment strategies.
🧬 GSK Finalizes $2 Billion Acquisition of Efimosfermin, a potential first-in-class drug combining siRNA and antifibrotic mechanisms to target steatotic liver diseases, including MASH and ALD.
📢 Stay Ahead in Immunology Research!
✅ Like, share, and subscribe for weekly updates on immunology and autoimmune innovation
#Immunology #AutoimmuneDisease #AtopicDermatitis #RheumatoidArthritis #VTAMA #Zabalafin #Pfizer #Abrocitinib #AIinHealthcare #ClinicalTrials #GSK #LupusResearch #DrugDevelopment #EMA #ImmunologyResearch #LucidQuest